How to get into Y Combinator, according to YC’s Dalton Caldwell
At TechCrunch Early Stage, Y Combinator's Dalton Caldwell shared insights on the application process — what works on an application, what doesn't, and the right ways to stand out.
Forsaking funding at a $1 billion valuation, Solugen preps a new green chemical product and a big 2021
Late last year, Solugen, a startup using synthetic biology to take hydrocarbons out of the chemicals industry, decided against pursuing a new round of funding that would have valued the company at ove
Genomatica’s expanded Aquafil partnership brings biomaterials to more consumer goods
In a deal that has potentially big implications for the sustainability of consumer packaged goods, biomaterial manufacturing technology developer Genomatica and the massive nylon material manufacturer
4 sustainable industries where founders and VCs can see green by going green
Now’s the time for sustainable investments to shine. There are billions of dollars in funding in both public and private markets dedicated to new sustainable investing and demand for consumers f
With Goat Capital, Justin Kan and Robin Chan want to keep founding alongside the right teams
Justin Kan and Robin Chan have each been angel investing for more than a decade. They’re starting a new fund together now, though, to stay involved as cofounders of more startups. Goat Capital is a
Synthetic biology startups are giving investors an appetite
There’s a growing wave of commercial activity from companies that are creating products using new biological engineering technologies. Perhaps the most public (and tastiest) example of the promi
We asked 12 Boston startups about their diversity efforts
It will take until 2085 for Black workers to reach the same hiring rate of white men in the industry today. For Latinos, it will take until 2045. And for women, it will take until 2070.
Emerging from stealth, Octant is bringing the tools of synthetic biology to large scale drug discovery
Octant, a company backed by Andreessen Horowitz just now unveiling itself publicly to the world, is using the tools of synthetic biology to buck the latest trends in drug discovery. As the pharmaceuti
Counting down Boston’s biggest venture rounds from 2019
Hello and welcome back to our regular morning look at private companies, public markets and the gray space in between. Today, the last day of 2019, we’re taking a second look at Boston. Regular
Startups Weekly: Upfront Ventures bets on a bus service
In this week's newsletter: Airbnb, WeWork and Postmates prep IPOs.
Ginkgo Bioworks’ dev shop for genetic programming is now worth $4 billion
Ginkgo Bioworks is now worth $4 billion after a $290 million capital infusion that will give the company the cash to dramatically expand its developer shop for genetic programming. The Boston-based co
Boston gets a new biotech accelerator with the launch of Petri
As biotechnology becomes more central to new innovations in healthcare, material science and manufacturing, one of the nation’s research hubs is getting a new accelerator called Petri to launch
Biotech researchers venture into the wild to start their own business
Much of Silicon Valley mythology is centered on the founder-as-hero narrative. But historically, scientific founders leading the charge for bio companies have been far less common.
Cannabis processing startups hope to unlock new chemicals and treatments
Jeff Ubersax knows yeast. The chief executive officer of Demetrix studied yeast genetics and biochemistry in school and was an early employee at Amyris Biotechnologies, a technology company that was u
From lab-grown meat to fermented fungus, here’s what corporate food VCs are serving up
We put together a list of venture funds operated by some of the larger food and beverage producers, covering literally everything from soup to nuts (plus lunch meat and soda, too!).
These are the most successful companies to emerge from Y Combinator
A look at the 20 most successful companies to come out of Y Combinator.
Ginkgo Bioworks secures $275 million in Series D, valuing the company at over $1 billion
Boston biotech startup Ginkgo Bioworks has announced the raise of $275 million in Series D funding to build out its Bioworks3 production facility. The funding comes from previous investors Viking Glo
Biotech startup Zymergen nabs $130 million from Softbank
Zymergen, a Bay Area startup creating all sorts of materials from genetically altered microbes, just raised $130 million in Series B funding from Softbank. For those unfamiliar, the company makes craz
Ginkgo Bioworks grabs $100 million in financing to buy a whole lot of synthetic DNA
Ginko Bioworks, the Boston-based biotech startup making all sorts of scents and flavors from microbugs, has pulled in $100 million in Series C funding to obtain 600 million base pairs of manufactured
Ginkgo Bioworks Takes On Zymergen With $45 Million In Series B Funding
Boston biotech startup Ginkgo Bioworks just gained an extra $45 million in Series B funding from an "oversubscribed" list of investors. The startup raised $9 million in March, so that gives the startu